Citations

Clear

6273 citation(s) found for "To, Andrew".

Postnatal Cardiometabolic Health After Metformin Use in Gestational Diabetes: A Secondary Analysis of the EMERGE Trial
Dunne, Fidelma , Newman, Christine , Alvarez‐Iglesias, Alberto , O’Shea, Paula , Gillespie, Paddy , O’Donnell, Martin , Smyth, Andrew , Gillespie, Paddy , Egan, Aoife, O'Shea, Paula M , Dunne, Fidelma P , Devane, Declan , Egan, Aoife M. , Newman, Christine

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 26, 2024 | Volume: 110 | Issue: 5 | Pages: e1566-e1572

10.1210/clinem/dgae522 | PMID 39056256 Get It

Abstract Aim Women with gestational diabetes mellitus (GDM) display adverse lifetime cardiometabolic health. We examined whether early metformin in GDM could impact cardiometabolic risk factors postpartum. Methods EMERGE, a double-blind, placebo-controlled trial, randomized pregnancies 1:1 to placebo or metformin at GDM diagnosis and followed participants from randomization until 12 ± 4 weeks postpartum. In total, 478 pregnancies were available for postpartum maternal assessment, 237 and 241 assigned to metformin and placebo respectively. Weight (kg), body mass index (BMI) (kg/m2), waist circumference (cm), and blood pressure (mmHg) were measured, infant feeding method documented, and blood specimens drawn for a 75-gram oral glucose tolerance test, fasting insulin, C-peptide, and lipid analysis. Results Despite similar weight and BMI at trial randomization, participants receiving metformin had significantly lower weight (79.5 ± 15.9 vs 82.6 ± 16.9 kg; P = .04) and BMI (29.3 [5.6] vs 30.5 [5.4]; P = .018) at the postpartum visit. However, no difference in weight change from randomization to 12 weeks postpartum was observed between metformin and placebo groups. Overall, 29% (n = 139) of the cohort met criteria for prediabetes or diabetes, with no positive impact with metformin. There were also no differences in measurements of insulin resistance, blood pressure, or lipids between groups. Conclusion Early metformin use in GDM did not impact important cardiometabolic parameters in the early postpartum period despite significant benefits in weight gain and insulin use in pregnancy.
Managing the OR: Tools, resources and guidelines to effectively manage operative suites
Pederson, Michael D., Abildgaard, Andrew S., Caplan, Sherry M., Krings, Ginger H., Krosch, Tara C., Linder, Lindsay E., Loeffler, Stephanie A., Paul, Travis C., Bhandari, Pawan , Anil, Gokhan , Pederson, Michael D., Mueller, Jennifer L., Paul, Travis C.

Mayo Clinic

Management in Healthcare: A Peer-Reviewed Journal | July 25, 2024 | Volume: 8 | Issue: 2 | Pages: 182

10.69554/edrv9615 Get It

As modern medicine offers novel surgical therapies for conditions simple and complex, the proper resource allocation of operating rooms, surgical staff and supporting services is becoming increasingly important for healthcare organisations. Surgical services are one of the most essential parts of any healthcare system, substantially influencing patient choice of healthcare services. These services are typically the centre for revenue but also impart considerable costs. Given the complexity of surgical schedule planning, expectations of high reliability and demand on resources, many healthcare organisations have resorted to using a static block schedule based on historic utilisation patterns. This is based on the dogma that surgical schedules are not predictable, surgical blocks are stable, and surgical yield has no direct correlation with outpatient schedules. Here we share our two-year experience with a Surgical Predictor Tool using our surgical practice management principles and the cost-effective use of these means to meet the needs of patients and our surgical staff in an integrated community health system.
Current Clinical Concepts: Rehabilitation of Thoracic Outlet Syndrome
Hock, Greg, Johnson, Andrew, Papa, Cassidy, Johnson, Andrew, Barber, Patrick, Johnson, Andrew

Mayo Clinic

Journal of Athletic Training | July 24, 2024 | Volume: 59 | Issue: 7 | Pages: 683-695

10.4085/1062-6050-0138.22 | PMID 39048118 Get It

Thoracic outlet syndrome (TOS) involves inconsistent symptoms, presenting a challenge for medical providers to diagnose and treat. Thoracic outlet syndrome is defined as a compression injury to the brachial plexus, subclavian artery or vein, or axillary artery or vein occurring between the cervical spine and upper extremity. Three common subcategories are now used for clinical diagnosis: neurogenic, arterial, and venous. Postural position and repetitive motions such as throwing, weightlifting, and manual labor can lead to symptoms. Generally, TOS is considered a diagnosis of exclusion for athletes due to the poor accuracy of clinical testing, including sensitivity and specificity. Thus, determining a definitive diagnosis and reporting injury is difficult. Current literature suggests there is not a gold standard diagnostic test. Rehabilitation has been shown to be a vital component in the recovery process for neurogenic TOS and for arterial TOS and venous TOS in postoperative situations.
A Randomized Comparison of Postprandial Glucose Excursion Using Inhaled Insulin Versus Rapid-Acting Analog Insulin in Adults With Type 1 Diabetes Using Multiple Daily Injections of Insulin or Automated Insulin Delivery
Hirsch, Irl B., Beck, Roy W. , Marak, Martin Chase , Calhoun, Peter , Mottalib, Adham , Salhin, Amna, Manessis, Anastasios , Bhargava, Anuj , Thorsell, Ashley, Atakov-Castillo, Astrid , Bode, Bruce W., Levister, Camilla, Donahue, Cassandra, Cordero, Christian, Beatson, Christie , Langel, Christine R., Jacobson, Christopher , Kurek, Corey, Cruse, Dana, Pickering, David, Tamarez, Denisa, Desjardins, Donna, O’Malley, Grenye , Aktürk, Halis Kaan , Diner, Jamie, Baran, Jesica D., Ruedy, Katrina J., Codorniz, Kevin , Klein, Klara R. , Castorino, Kristin , Jordan, L.F., Kipnes, Mark, Church, Mei Mei , Raskin, Philip, Nguyen, Quang T., Weinstock, Ruth S. , Rizvi, Shafaq, Bzdick, Suzan, Rodriguez, Tahereh Ghorbani, Salah, Tareq , Blevins, Thomas , Kudva, Yogish C. , Haider, Zehra, Group, INHALE-3 Study, Bode, Bruce W., Ownby, Jonathan G., Johnson, Joseph H., Ruiz, Adriana, Stephens, Nashia, Maxson, Amanda, Beatson, Christie, Mason, E E , Steenkamp, Devin W., Wolpert, Howard , Sullivan, Asya, Salhin, Amna, Copple, Tina, Beltran, Stephanie, Ryan, Terri, O’Malley, Grenye, Tamarez, Denisa, Ipek, Aslihan, Burke, Christine, Langel, Christine, Bauman, Shannon , Haight, Cristina, Bohr, A., Badri, Marwa Al, Nguyen, Loida, Cordero, Christian, Migliozzi, Brittney, Reid, Corey, Kaur, Ravinder Jeet , Livingood, Daine, Cruse, Dana, Kravarusic, Jelena, Coyne, Kasey, Herrmann, Stefanie, Fronczyk, Evelyn, McKillop, Lorcan, Hyatt, Jamie, Patruno, Maria, Shuirman, Maggie, Cobb, Brandon, Watt, Olivia, Casaubon, Luis, Espinosa, Valerie, Pandit, Keta, Perez, Jennifer, Armstrong, Chloe, Martinez-Arredondo, Maritza, Stewart, Ana, Rodriguez, Tahereh Ghorbani, Young, Laura , Kass, Alexander, Fulghum, Karla, Jordan, Lin, Shao, Baomei, Baran, Jesica, Mandava, Patali, Holod, Rosanna, Kaiserman, Kevin B. , Ulloa, Johanna, Pleitez, Jennifer, Sylvan, Joey, Badgett, Lynn, Borgman, Sarah, Frey, Sarah, Mba-Oduwusi, Nnenna, Miller, Paige , Fults, Ashleigh, Marak, Martin, Pritchard, Rosa, Dolzhenko, E. N. , Gabrielson, Deanna, Brown, Sue A. , Ahmann, Andrew , Bergenstal, Richard M. , Levy, Carol J , Steenkamp, Devin W , Aleppo, Grazia , Akturk, Halis K , Klein, Klara R , Castorino, Kristin , Church, Mei Mei , Hamdy, Osama , Weinstock, Ruth S , Salah, Tareq , Kudva, Yogish C. , Beck, Roy W , Calhoun, Peter , Coviello, Andrea D. , Bode, Bruce W., Levy, Carol J. , Donahue, Cassandra, Aleppo, Grazia , Buse, John B. , Nguyen, Quang T., Lee, Scott Jeffery , Group, INHALE-3 Study, Bode, Bruce W., Beatson, Christie, Mason, Emma, Steenkamp, Devin W., Salhin, Amna, O’Malley, Grenye, Bauman, Shannon, Dhaver, Shilton , Nguyen, Quang T., Cordero, Christian, Cruse, Dana, Johnson, Olivia, Rodriguez, Tahereh Ghorbani, Miller, Paige, McCarthy, Chris

Mayo Clinic

Diabetes Care | July 23, 2024 | Volume: 47 | Issue: 9 | Pages: 1682-1687

10.2337/dc24-0838 | PMID 39042575 Get It

OBJECTIVE To compare postprandial glucose excursions following a bolus with inhaled technosphere insulin (TI) or subcutaneous rapid-acting analog (RAA) insulin. RESEARCH DESIGN AND METHODS A meal challenge was completed by 122 adults with type 1 diabetes who were using multiple daily injections (MDI), a nonautomated pump, or automated insulin delivery (AID) and who were randomized to bolus with their usual RAA insulin (n = 61) or TI (n = 61). RESULTS The primary outcome, the treatment group difference in area under the curve for glucose >180 mg/dL over 2 h, was less with TI versus RAA (adjusted difference −12 mg/dL, 95% CI −22 to −2, P = 0.02). With TI, the glucose excursion was smaller (P = 0.01), peak glucose lower (P = 0.01), and time to peak glucose shorter (P = 0.006). Blood glucose <70 mg/dL occurred in one participant in each group. CONCLUSIONS Postmeal glucose excursion was smaller with TI than with RAA insulin in a cohort that included both AID and MDI users.
Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model
Leuzy, Antoine , Villemagne, Victor L. , Klein, Gregory , Tonietto, Matteo, Olafson, Emily, Baker, Suzanne L. , Saad, Ziad S., Bullich, Santiago , Lopresti, Brian J. , Boada, Merçé , Charil, Arnaud , Collins, Emily C. , Collins, Jessica , Cullen, Nicholas , Gunn, Roger N. , Higuchi, Makoto , Hostetler, Eric D., Hutchison, R. Matthew , Irizarry, Michael C. , Jack, Clifford R. , Jagust, William J. , Karten, Yashmin, Marquié, Marta , Mathotaarachchi, Sulantha , Mintun, Mark A., Pappas, Ioannis , Petersen, Ronald C. , Rabinovici, Gil D. , Stephens, Andrew , Whittington, Alex , Carrillo, Marı́a C., Pontecorvo, Michael J. , Haeberlein, Samantha Budd , Dunn, Billy , Kolb, Hartmuth C. , Doré, Vincent , Carrillo, María C. , Jack, Clifford R , Boada, Merce , Rabinovici, Gil D , Doré, Vincent , Rakêt, Lars Lau , Tonietto, Mattéo , Bohórquez, Sandra Sanabria , Betthauser, Tobey J. , Iaccarino, Leonardo , Insel, Philip S. , Johnson, Sterling C. , Ossenkoppele, Rik , Rosa-Neto, Pedro , Schwarz, Christopher G. , Smith, Ruben , Sivakumaran, Sudhir , Rowe, Christopher Cleon , Hansson, Oskar

Mayo Clinic

Alzheimer's & Dementia | July 23, 2024 | Volume: 20 | Issue: 9 | Pages: 5833-5848

10.1002/alz.13908 | PMID 39041435 Get It

Abstract INTRODUCTION Tau‐positron emission tomography (PET) outcome data of patients with Alzheimer's disease (AD) cannot currently be meaningfully compared or combined when different tracers are used due to differences in tracer properties, instrumentation, and methods of analysis. METHODS Using head‐to‐head data from five cohorts with tau PET radiotracers designed to target tau deposition in AD, we tested a joint propagation model (JPM) to harmonize quantification (units termed “CenTauR” [CTR]). JPM is a statistical model that simultaneously models the relationships between head‐to‐head and anchor point data. JPM was compared to a linear regression approach analogous to the one used in the amyloid PET Centiloid scale. RESULTS A strong linear relationship was observed between CTR values across brain regions. Using the JPM approach, CTR estimates were similar to, but more accurate than, those derived using the linear regression approach. DISCUSSION Preliminary findings using the JPM support the development and adoption of a universal scale for tau‐PET quantification. Highlights Tested a novel joint propagation model (JPM) to harmonize quantification of tau PET. Units of common scale are termed “CenTauRs”. Tested a Centiloid‐like linear regression approach. Using five cohorts with head‐to‐head tau PET, JPM outperformed linearregressionbased approach. Strong linear relationship was observed between CenTauRs values across brain regions.
Cerebrospinal Fluid Cytokine and Chemokine Profiles in Central Nervous System Sarcoidosis: Diagnostic and Immunopathologic Insights
Mangioris, Georgios , Pittock, Sean J. , Yang, Binxia , Fryer, James P., Harmsen, William S. , Dubey, Divyanshu , López‐Chiriboga, A. Sebastian , McKeon, Andrew , Mills, John R. , Vodopivec, Ivana, Toledano, Michel , Aksamit, Allen J. , Ζεκερίδου, Αναστασία , Pittock, S J , Flanagan, E P , Lopez-Chiriboga, A Sebastian , McKeon, Andrew , Tobin, W Oliver , Toledano, Michel , Zekeridou, Anastasia , Dubey, Divyanshu , Yang, Binxia , Flanagan, Eoin P. , Tobin, W. Oliver

Mayo Clinic

Annals of Neurology | July 19, 2024 | Volume: 96 | Issue: 4 | Pages: 704-714

10.1002/ana.27024 | PMID 39031103 Get It

ObjectiveTo evaluate the cerebrospinal fluid (CSF) cytokine/chemokine profile of central nervous system (CNS) neurosarcoidosis (NS), and its utility in differential diagnosis, treatment, and prognostication.MethodsIn this case–control study, we validated 17 cytokines/chemokines (interleukin [IL]‐1‐beta, IL‐2, IL‐4, IL‐5, IL‐6, IL‐10, IL‐12p70, IL‐13, IL‐17A, BAFF, IL‐8/CXCL8, CXCL9, CXCL10, CXCL13, GM‐CSF, interferon‐gamma, and tumor necrosis factor [TNF]‐alpha) in a multiplexed automated immunoassay system (ELLA; Bio‐Techne, Minneapolis, MN, USA), and assessed them in CSF and serum of symptomatic patients with probable or definite CNS NS (01/2011–02/2023) with gadolinium enhancement and/or CSF pleocytosis. Patients with multiple sclerosis, primary CNS lymphoma, aquaporin‐4 immunoglobulin G positivity, non‐inflammatory disorders, and healthy individuals were used as controls.ResultsA total of 32 NS patients (59% women; median age, 59 years [19–81]) were included; concurrent sera were available in 12. CSF controls consisted of 26 multiple sclerosis, 8 primary CNS lymphoma, 84 aquaporin‐4 immunoglobulin G positive, and 34 patients with non‐inflammatory disorders. Gadolinium enhancement was present in 31 of 32 NS patients, and CSF pleocytosis in 27 of 32 (84%). CSF IL‐2, IL‐6, IL‐10, IL‐13, BAFF, IL‐8/CXCL8, CXCL9, CXCL10, CXCL13, GM‐CSF, interferon‐gamma, and TNF‐alpha levels were significantly higher in NS patients compared with non‐inflammatory controls (p ≤ 0.02); elevations were more common in CSF than serum. Concurrent elevation of IL‐6, CXCL9, CXCL10, GM‐CSF, interferon‐gamma, and TNF‐alpha was present in 18 of 32 NS patients, but only in 1 control. Elevated IL‐6, IL‐10, IL‐13, CXCL9, CXL10, GM‐CSF, and TNF‐alpha associated with measures of disease activity.InterpretationNS CSF cytokine/chemokine profiles suggest T cell (mainly T helper cell type 1), macrophage, and B‐cell involvement. These signatures aid in NS diagnosis, indicate disease activity, and suggest therapeutic avenues. ANN NEUROL 2024;96:704–714
Subclinical aortic inflammation in patients with polymyalgia rheumatica
Kaymakci, Mahmut , Berry, Gerald J. , Langenfeld, Hannah E., Hanson, Andrew C. , Crowson, Cynthia S. , Bois, Melanie C. , Sato, Yuki , Le, Kevin , Weyand, Cornelia M. , Kaymakci, Mahmut S , Le, Kevin-Phu C , Warrington, Kenneth J , Berry, Gerald J , Schaff, Hartzell V. , Le, Kevin-Phu C, Koster, Matthew J. , Warrington, Kenneth J.

Mayo Clinic

Rheumatology | July 18, 2024 | Volume: 63 | Issue: 12 | Pages: 3289-3296

10.1093/rheumatology/keae373 | PMID 39024049 Get It

Abstract Objectives To examine the clinicopathologic features of patients with polymyalgia rheumatica (PMR) who had thoracic aorta repair surgery. Findings were compared with those of a cohort of patients with giant cell arteritis (GCA) requiring thoracic aorta repair. Methods All patients evaluated at Mayo Clinic in Rochester, MN, with Current Procedural Terminology (CPT) codes for thoracic aorta repair surgery between 2000–2021 were identified. All patients were screened for prior PMR diagnosis. Patients with PMR and no signs of GCA were categorized as clinically isolated PMR. The medical records of all patients were manually reviewed, and pathologists re-examined all the aortic tissues. Results Of the 4621 patients with at least one CPT code for thoracic aorta repair surgery, 43 patients were diagnosed with clinically isolated PMR before the surgery. Detailed histopathological examination of the aortic tissues revealed active inflammation in 30/43 (70%) patients after a median (IQR) of 10.0 (4.7–13.3) years from the PMR diagnosis. When compared with aortic tissue from patients with a prior diagnosis of GCA, the aorta of patients with PMR had more severe inflammation (Grade 3: 15/30 [50%] vs 5/34 [15%], P = 0.002). Patients with PMR and thoracic aorta repair may experience a 40% increased risk of mortality compared with the general population, but this did not reach statistical significance (standardized mortality ratio: 1.40; 95% CI: 0.91–2.07). Conclusions Some patients with PMR have subclinical aortic inflammation that is detectable many years after initial diagnosis and may contribute to the development of aortic aneurysm.
IFTA Foci Density: An Unrecognized Highly Prognostic Measurement of Fibrosis in Kidney Transplant Biopsies
Đenić, Aleksandar , Rule, Andrew D., Park, Walter D. , Smith, Byron H. , Mejia, Mateo Velasquez , Kukla, Aleksandra , Grande, Joseph P. , Smith, Byron , Denic, Aleksandar , Park, Walter , Rule, Andrew D. , Stegall, Mark D.

Mayo Clinic

Kidney360 | July 18, 2024 | Volume: 5 | Issue: 9 | Pages: 1341-1349

10.34067/kid.0000000000000514 | PMID 39024036 Get It

Key Points Morphometry allows for a more prognostic multidimensional quantification of interstitial fibrosis and tubular atrophy (IFTA) in kidneys than does visual inspection. The density of IFTA foci is determined by dividing the number of contiguous IFTA patches in the kidney cortex by the area of cortex. Higher density of IFTA foci significantly predicted renal allograft failure beyond %IFTA and other biopsy and clinical characteristics. Background Contraction of interstitial fibrosis and tubular atrophy (IFTA) may cause %IFTA to under-represent the severity of nephron loss. Higher density of IFTA foci is an important predictor of progressive CKD in native kidneys independent of %IFTA. Methods We studied kidney transplant recipients transplanted between 2000 and 2013 who had a 5-year surveillance kidney biopsy and subsequent follow-up. Banff ci score (interstitial fibrosis) was obtained from the pathology reports. After digitizing the biopsies, we traced cortex area and each distinct IFTA focus on a single trichrome-stained section. Percent IFTA area and IFTA foci density (count of IFTA foci/cortex area) were calculated. Cox models assessed the risk of death-censored graft failure after the 5-year biopsy with Banff ci score, morphometric %IFTA, and IFTA foci density. Results There were 58 death-censored allograft failures among 835 kidney recipients during the 5 years of follow-up. Biopsies from grafts that failed had higher mean Banff ci score (1.5 versus 0.7, P < 0.0001), %IFTA (22.6% versus 7.0%, P < 0.0001), and IFTA foci density (1.3/mm 2 versus 0.4/mm 2 , P < 0.0001). After adjusting for other Banff scores or clinical variables, Banff ci did not correlate with allograft failure, but both higher %IFTA (hazard ratio = 1.56, P < 0.0001) and higher IFTA foci density (hazard ratio = 2.34, P < 0.0001) did. All but four allograft failures by 10 years had biopsies in the top quartile of either %IFTA or IFTA foci density at 5 years. A model using just these two morphometric measures without clinical characteristics resulted in a c-statistic of 0.891 with respect to allograft failure. Conclusions Morphometric characterization of IFTA foci density is a strong predictor of death-censored allograft failure not captured in current Banff classification for grading of kidney fibrosis.
Quality of life and patient‐reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy
Hoogland, Aasha I. , Michael, Lauren, Wuthrick, Evan , Eroglu, Zeynep , Blakaj, Dukagjin , Jim, Heather , Kim, Sungjune, Jim, Heather S L , Brohl, Andrew S. , Small, Brent J. , Verschraegen, Claire F , Khushalani, Nikhil I.

Mayo Clinic

Cancer Medicine | July 18, 2024 | Volume: 13 | Issue: 14 | Pages: No page available

10.1002/cam4.7464 | PMID 39021272 Get It

AbstractBackgroundMerkel cell carcinoma is a rare skin cancer associated with poor survival. Based on a previous Phase II trial of adults with advanced Merkel cell carcinoma by Kim and colleagues (2022), there is now a strong rationale for combination therapy (i.e., nivolumab and ipilimumab) to become a treatment option for patients with advanced Merkel cell carcinoma. The goal of this paper was to report on the secondary outcome of quality of life (QOL) among patients on this trial.MethodsPatients receiving combined nivolumab and ipilimumab, with or without stereotactic body radiation therapy (SBRT), completed the European Organisation for Research and Treatment of Cancer (EORTC) QLQ‐C30 prior to starting treatment and every 2 weeks thereafter. Changes in QOL during treatment and post‐treatment were evaluated using piecewise random‐effects mixed models. Exploratory analyses compared changes in QOL between study arms. The original trial was registered with ClinicalTrials.gov (NCT03071406).ResultsStudy participants (n = 50) reported no changes in overall QOL (ps > 0.05), but emotional functioning improved during treatment (p = 0.01). Cognitive and social functioning worsened post‐treatment (ps < 0.01). In general, patients treated with combination therapy only (n = 25) reported no change in QOL over time, whereas patients also treated with SBRT (n = 25) consistently demonstrated worsening QOL post‐treatment.ConclusionQOL is generally preserved in patients treated with combination therapy, but the addition of SBRT may worsen QOL. Combined with clinical efficacy data published previously, results support the use of combination therapy with nivolumab and ipilimumab as a treatment option for patients with advanced Merkel cell carcinoma.
Transcatheter vs. surgical mitral valve interventions in patients with prior coronary artery bypass grafting
Ismayl, Mahmoud , Ahmed, Hasaan , Goldsweig, Andrew M. , Alkhouli, Mohamad , Eleid, Mackram F. , Rihal, Charanjit S. , Goldsweig, Andrew M , Ismayl, Mahmoud , Alkhouli, Mohamad , Rihal, Charanjit S. , Guerrero, Mayra

Mayo Clinic

European Heart Journal - Quality of Care and Clinical Outcomes | July 18, 2024 | Volume: 11 | Issue: 5 | Pages: 539-553

10.1093/ehjqcco/qcae060 | PMID 39030048 Get It

Abstract Background A significant proportion of patients requiring mitral valve (MV) intervention have undergone prior coronary artery bypass grafting (CABG). Reoperative heart surgery is associated with increased risk. Aims To evaluate the utilization and outcomes of transcatheter vs. surgical MV interventions in patients with prior CABG. Methods We queried the Nationwide Readmission Database (2016–21) to identify adults with prior CABG hospitalized for transcatheter or surgical MV intervention. In-hospital outcomes were compared using multivariable regression and propensity-matching analyses. Readmissions were compared using Cox proportional hazards regression model. Results Of 305 625 weighted hospitalizations for MV intervention, 23 506 (7.7%) occurred in patients with prior CABG. From 2016Q1–2021Q4, the use of transcatheter MV interventions increased among patients with prior CABG (72 to 191 for repair and 6 to 45 for replacement per 100 000 hospitalizations, both ptrend &lt; 0.001). Compared with surgical MV repair and replacement, transcatheter MV repair and replacement were associated with similar in-hospital mortality (adjusted odds ratio [aOR] 0.44, 95% confidence interval [CI] 0.20–1.03 for repair; aOR 0.61, 95% CI 0.38–1.02 for replacement) and 180-day heart failure (HF) readmissions (adjusted hazard ratio [aHR] 1.56, 95% CI 0.85–2.87 for repair; aHR 1.15, 95% CI 0.63–2.09 for replacement) and lower stroke, acute kidney injury, permanent pacemaker placement, length of stay, and non-home discharges, respectively. Vascular complications were higher with transcatheter vs. surgical MV replacement. Conclusion Transcatheter MV interventions are increasingly used as the preferred modality of MV intervention in patients with prior CABG and are associated with similar in-hospital mortality and 180-day HF readmissions compared with surgical MV interventions.